Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bristol-Myers Squibb reports positive multiple myeloma drug trial data

Bristol-Myers Squibb reports positive multiple myeloma drug trial data

3rd June 2015

Bristol-Myers Squibb has announced the publication of clinical trial data showing the positive impact its investigational agent elotuzumab can deliver for multiple myeloma patients.

An interim analysis of the phase III ELOQUENT-2 trial has been published in the New England Journal of Medicine, showing how the immunostimulatory antibody, when used in combination with lenalidomide and dexamethasone, can be an effective treatment for relapsed or refractory multiple myeloma.

The new therapy, developed in partnership with AbbVie, delivered a 30 percent reduction in the risk of disease progression or death, with the two-year progression-free survival rate of 41 percent, compared to 27 percent among those on standard treatment.

Meanwhile, its safety profile showed minimal incremental adverse events with the addition of elotuzumab to lenalidomide and dexamethasone.

Michael Giordano, senior vice-president and head of development for oncology at Bristol-Myers Squibb, said: "Bristol-Myers Squibb continues to make great progress toward delivering on our commitment to expand the role of immunotherapy into haematologic malignancies, such as multiple myeloma."

This comes after the firm recently presented new data on elotuzumab at the American Society of Clinical Oncology's annual meeting.ADNFCR-8000103-ID-801789786-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.